Variable |
Total no. (missing data) |
No. (%) cases/y |
Average incidence, cases/100,000 population/y |
---|---|---|---|
Age, y | 319 (0) | ||
<1 y | 118 (37.0) | 31.5 | |
1–4 | 120 (37.6) | 8.2 | |
5–9 | 46 (14.4) | 2.6 | |
10–14 | 35 (11.0) | 2.0 | |
Sex | 319 (0) | ||
F | 125 (39.2) | 4.8 | |
M | 194 (60.8) | 7.0 | |
Ethnicity, prioritized | 319 (0) | ||
Māori | 114 (35.7) | 11.6 | |
Pacific | 140 (43.9) | 13.4 | |
Non-Māori, non-Pacific | 65 (20.4) | 1.9 | |
New Zealand Index of Deprivation Quintile† | 317‡ | ||
1 | 11 (3.5) | NA | |
2 | 21 (6.6) | NA | |
3 | 42 (13.2) | NA | |
4 | 54 (17.0) | NA | |
5 | 189 (59.6) | NA | |
Clinical manifestations | 319 (0) | ||
Bacteremia only | 108 (33.9) | NA | |
Meningitis only | 63 (19.7) | NA | |
Meningitis with bacteremia | 138 (42.3) | NA | |
Septic arthritis only | 5 (1.6) | NA | |
Septic arthritis with bacteremia | 2 (0.6) | NA | |
Meningitis and septic arthritis with bacteremia | 3 (0.9) | NA | |
Vital signs on first presentation | |||
Temperature >38·5°C or <36°C | 314 (5) | 150 (47.7) | NA |
Systolic hypotension for age | 218 (101) | 84 (38.5) | NA |
Impaired level of consciousness | 291 (28) | 99 (34.0) | NA |
Clinical signs at first presentation | |||
Rash in cases with bacteremia | 248 (3) | 213 (85.9) | NA |
Includes purpura | 213 (3) | 108 (50.7) | NA |
Includes petechiae without purpura | 213 (3) | 86 (40.4) | NA |
Blanching only | 213 (3) | 19 (8.9) | NA |
Meningism in cases with meningitis | 184 (20) | 111 (60.3) | NA |
Bulging fontanelle in infants with meningitis | 43 (39) | 19 (44.2) | NA |
Arthritis during admission | 314 (5) | 19 (6.1) | NA |
Arthralgia during admission | 314 (5) | 23 (7.3) | NA |
Table 1. Demographic and clinical factors of 319 confirmed cases of invasive meningococcal disease in children <15 years of age, Auckland, New Zealand, 2004–2020*
*NA, not applicable.
†Each NZDep quintile contains ≈20% of the population. 1 = least deprived; 5 = most deprived.
‡Two overseas cases were excluded.
Outcome |
No. cases/total no. (%) |
---|---|
Died | 13/319 (4.1) |
Cure, complete outcome data | 258/306 (84.3) |
Cure, incomplete outcome data | 48/306 (15.6) |
Cure without sequelae | 197/258 (76.4) |
Cure with sequelae | 61/258 (23.6) |
Sequelae | |
Neurodevelopmental | 35/258 (13.6) |
Sensorineural hearing loss | 32/258 (12.4) |
Skin scarring | 16/258 (6.2) |
Loss of limbs or digits | 7/258 (2.7) |
Chronic kidney disease | 1/258 (0.4) |
Other sequelae* | 5/258 (1.9) |
Neurodevelopmental sequelae | |
Delayed development | 20/258 (7.8) |
Cerebral ischemia | 13/258 (5) |
Epilepsy | 8/258 (3.1) |
Learning, concentration, behavior, psychological | 8/258 (3.1) |
Other† | 10/258 (3.9) |
Table 2. Outcomes of 319 confirmed cases of invasive meningococcal disease in children <15 years of age, Auckland, New Zealand, 2004–2020
*Other: bone growth arrest 2/258 (0.8%); cardiomyopathy 1/258 (0.4%); gastrointestinal hemorrhage 1/258 (0.4%); panniculitis 1/258 (0.4%). †Other neurodevelopmental: chronic hydrocephalus 2/258 (0.8%); autism spectrum disorder 1/258 (0.4%); ataxia 1/258 (0.4%); carotid artery narrowing 1/258 (0.4%); chronic headache 1/258 (0·4%); cranial nerve palsy 1/258 (0.4%); encephalomalacia 1/258 (0.4%); hypertonia 1/258 (0.4%); syringomyelia 1/258 (0.4%).
Variable |
No. cases (%) |
OR (95% CI) |
p value |
---|---|---|---|
Ethnicity, compared with non-Māori, non-Pacific population | |||
Pacific | 38/118 (32.2) | 2.91 (1.31–7.18) | 0.0128 |
Māori | 28/96 (29.2) | 2.52 (1.10–6.35) | 0.0366 |
Reduced penicillin susceptibility | 12/64 (18.8) | 0.548 (0.25–1.14) | 0.117 |
NZDep quintile† | 271 | 1.21 (0.95–1.58) | 0.142 |
Age, mo† | 271 | 0.996 (0.99–1.00) | 0.157 |
Serogroup, compared with MenB | |||
MenC | 7/18 (38.9) | 1.80 (0.64–4.82) | 0.247 |
MenW | 6/25 (24.0) | 0.89 (0.31–2.24) | 0.822 |
MenY | 3/8 (37.5) | 1.70 (0.34–7.16) | 0.478 |
Male sex, compared with female | 50/168 (29.8) | 1.39 (0.80–2.48) | 0.248 |
Season, compared with autumn | |||
Spring | 23/76 (30.3) | 1.47 (0.64–3.60) | 0.374 |
Summer | 11/35 (31.4) | 1.56 (0.57–4.31) | 0.386 |
Winter | 30/116 (25.9) | 1.19 (0.54–2.79) | 0.683 |
MeNZB vaccination, compared with fully vaccinated | |||
Unvaccinated | 43/166 (25.9) | 0.76 (0.39–1.51) | 0.425 |
Partially vaccinated | 12/41 (29.3) | 0.90 (0.37–2.17) | 0.817 |
Prehospital parenteral antibiotic treatment | 10/44 (22.7) | 0.79 (0.35–1.64) | 0.537 |
Sepsis criteria | 39/145 (26.9) | 1.14 (0.51–2.77) | 0.751 |
Table 3. Univariate logistic regression for combined outcome of death or sequelae in 271 confirmed cases of invasive meningococcal disease in children <15 years of age, Auckland, New Zealand, 2004–2020*
*Men, Neisseria meningitidis serogroup; OR, odds ratio; NZDep, New Zealand Index of Deprivation
†Continuous variable; OR represents increase in odds for each unit increase in variable.
Physicians - maximum of 1.00 AMA PRA Category 1 Credit(s)™
ABIM Diplomates - maximum of 1.00 ABIM MOC points
This activity is intended for primary care physicians, pediatricians, infectious disease specialists, and other clinicians who treat and manage children at risk for infection with Neisseria meningitidis.
The goal of this activity is for learners to be better able to evaluate the epidemiology, clinical features, and outcomes of pediatric invasive meningococcal disease.
Upon completion of this activity, participants will:
Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.
Medscape, LLC designates this Journal-based CME activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]
There are no fees for participating in or receiving credit for this online educational activity. For information on applicability
and acceptance of continuing education credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within the time designated on the title page; physicians should claim only those
credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the
activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.
Follow these steps to earn CME/CE credit*:
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it.
Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print
out the tally as well as the certificates from the CME/CE Tracker.
*The credit that you receive is based on your user profile.
processing....
We reviewed data from 331 cases, excluding 12 cases (6 in nonresidents, 5 that were noninvasive disease, and 1 that lacked sufficient data). The remaining 319 cases of laboratory-confirmed IMD occurred in 318 children. One child had 2 unrelated episodes of IMD that occurred in 2006 and 2017. There were no documented relapses after treatment in the cohort. The average annual incidence of IMD across the study period was 5.9/100,000 population. Incidence rates declined from the tail end of the epidemic in 2004 to a nadir in 2014, then increased to a second peak in 2019 (Figure 1). Overall, we found a trend toward reduced incidence over the study period (Poisson coefficient −0.07 [95% CI −0.14 to −0.01; p<0.01]; rate ratio 0.92 [95% CI 0.90–0.95]). Cases were more common in winter (135/319, 42.3%), followed by spring (87/319, 27.3%), autumn (52/319, 16.3%), and summer (45/319, 14.1%) (p<0.0001).
Figure 1. Timeline of 319 cases of confirmed invasive meningococcal disease in children <15 year of age, by serogroup, reported by year, Auckland, New Zealand, 2004–2020. Numbers along data line indicate exact rates for all cases by year. Men, Neisseria meningitidis serogroup.
Median age at time of diagnosis was 18 months (interquartile range [IQR] 7–60 months). The highest average incidence rates were among infants <1 year of age (31.5/100,000 population/year), followed by those 1–4 years of age (8.2/100,000 population/year), 5–9 years of age (2.6/100,000 population/year), and 10–14 years of age (2.0/100,000 population/year) (Table 1). Average incidence rates by ethnic group were highest in Pacific peoples (13.4/100,000 population/year), followed by Māori (11.6/100,000 population/year) and those who were neither Māori or Pacific (1.9/100,000 population/year) (Table 1). Based on census data and compared with non-Māori and non-Pacific groups, the unadjusted relative risk of IMD was 5.9 (95% CI 4.4–8.1) for Māori (p<0.0001) and 6.9 (95% CI 5.1–9.3) for Pacific peoples (p<0.0001). Most children (189/317, 59.6%) lived in NZDep quintile 5 (most deprived 20%) areas. The unadjusted relative risk of IMD for children living in NZDep quintile 5 areas compared with quintile 1 areas was 17.2 (95% CI 9.7–33.2; p<0.0001).
Of the 319 cases, we confirmed a microbiological diagnosis by both culture and PCR for 81 (25.4%), on culture alone for 114 (35.7%), and on PCR alone for 124 (38.9%). We compared N. meningitidis culture and PCR from blood and from CSF (Appendix Table 1). Blood culture was negative for 56 (78.9%) of 71 cases in children who received antibiotics before hospital admission (odds ratio 5.1 [95% CI 2.7–9.5]) compared with no prehospital antibiotics (p<0.0001). Of those 56 cases, N. meningitidis blood PCR was positive in all 50 cases tested. CSF analysis was performed in 138 (67.6%) of the 204 cases classified as meningitis (Appendix Table 2). CSF leukocytosis for age was present in 130 (97.7%) of 133 cases of meningitis where a CSF leukocyte count was performed. The serogroup was identified for 301 (94.4%) of the 319 cases: 245 (81.4%) were MenB, 26 (8.6%) MenW, 19 (6.3%) MenC, and 11 (3.7%) serogroup Y. Beginning in 2017, there was an increase in disease caused by MenW, which accounted for 8 (29.6%) of the 27 cases serogrouped in 2019; MenB was the remaining predominant serogroup (Figure 2). The epidemic B:P1.7–2,4 strain accounted for 135 cases (44.9%), waning over time, from 42 cases (14.0/100,000 population) in 2004 to 3 cases (0.90/100,000 population) in 2020 (Poisson coefficient −0.20 [95% CI −0.28 to −0.11]; p<0.01; rate ratio 0.82 [95% CI 0.78–0.85]). The proportion of isolates with reduced penicillin susceptibility increased during the study period. A MIC of >0.06 mg/L was identified in 28 (22.6%) of 124 isolates in 2004–2012 and 47 (66.2%) of 71 isolates in 2013–2020 (p<0.0001). Reduced penicillin susceptibility was identified in 20 (76.9%) of 26 MenW isolates compared with 55 (32.5%) of 169 non-MenW isolates (p = 0.012). All isolates were susceptible to ceftriaxone, ciprofloxacin, and rifampin.
Figure 2. Timeline of 319 cases of confirmed invasive meningococcal disease in children <15 years of age by age group (A) and prioritized ethnicity (B), reported by year, Auckland, New Zealand, 2004–2020.
The median duration of illness before care was sought was 1 day (IQR 1–3 days). Bacteremia was present in 251 cases (78.7%), meningitis in 204 (63.9%), and septic arthritis in 10 (3.1%) (Table 1). Concomitant bacteremia and meningitis occurred in 141 (44.2%) cases. No cases of chronic meningococcemia were recorded. Sepsis occurred in 172 (80.8%) of the 213 cases with complete systemic inflammatory response syndrome data.
Of the 319 cases, 317 (99%) were treated in a hospital; 2 children (0.6%) died before arrival. The median duration of hospitalization was 5 nights (IQR 3–7 nights). Prehospital parenteral antibiotics were administered in 52 (16.3%) cases. In the hospital, empiric antibiotics included a third-generation cephalosporin in 294 (92.7%) cases. There were 303 children who completed a full targeted treatment course of antibiotics, which included a third-generation cephalosporin in 230 cases (75.9%), benzylpenicillin in 67 cases (22.1%), amoxicillin in 8 cases (2.6%), and another antibiotic in 4 cases (1.3%). The median duration of antibiotic treatment was 5 days (IQR 5–7 days). Dexamethasone was administered in 47 (23%) of the 204 meningitis cases. Of the 100 (31.3%) children who were admitted to an ICU (median duration of stay 1 night [IQR 1–3 nights]), 55 received ≥1 life-saving measure: 46 received invasive ventilation, 44 received inotropic/vasopressor support, and 7 received renal replacement therapy. Plastic surgical procedures were performed in 12 (3.8%) cases, orthopedic procedures in 12 (3.8%), and neurosurgical procedures in 6 (1.9%).
Thirteen children died, resulting in a CFR of 4.1% (Table 2). The average death rate over the study period was 0.24/100,000 population/year. Of the 13 children who died (Appendix Table 3), 12 (92.3%) were Māori or Pacific peoples, 11 (84.6%) were living in NZDep quintile 5 areas, and 9 (69.2%) were infants <1 year of age. Ten deaths (76.9%) occurred in the community or within the first 48 hours of hospitalization. Of the 306 survivors, outcome data were complete for 258 cases (84.3%): cure without sequelae occurred in 197 (76.4%) and cure with sequelae 61 (23.6%). We classified outcome as unknown in 48 cases; all had meningitis with no available audiometry results (none had other sequelae identified on follow-up). Documented audiologic assessment occurred in 143 (72.6%) of 197 cases after meningitis. Of the 142 cases with audiometry results available, 32 (22.5%) had sensorineural impairment. Māori children with IMD had 2.5 (95% CI 1.1–6.4) times the odds for death or sequelae compared with non-Māori, non-Pacific peoples (p = 0.0366) (Table 3). Pacific peoples with IMD had 2.9 (95% CI 1.3–7.2) times the odds for death or sequelae compared with non-Māori, non-Pacific peoples (p = 0.0128). Results of univariate comparisons of age, sex, NZDep quintile, season, MeNZB vaccination status, sepsis criteria, serogroup, reduced penicillin susceptibility, and prehospital parenteral antibiotics were not significant.
Of the 163 children with complete vaccination records who were eligible for MeNZB, 114 (69.9%) had received ≥1 dose and 64 (39.3%) were fully vaccinated at time of hospital admission. For the 97 eligible children with vaccine subtype IMD, 55 (56.7%) had received ≥1 dose and 31 (32%) were fully vaccinated at time of hospital admission. The mean number of days between the date of last MeNZB vaccine and IMD onset increased with the number of doses received (p<0.00027) (Appendix Table 4).